Head-To-Head Review: RYTHM (RYM) versus Its Competitors

RYTHM (NASDAQ:RYM) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare RYTHM to similar businesses based on the strength of its risk, valuation, dividends, profitability, analyst recommendations, institutional ownership and earnings.

Insider & Institutional Ownership

6.0% of RYTHM shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares RYTHM and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
RYTHM	$17.28 million	-$33.26 million	-2.19
RYTHM Competitors	$16.93 billion	$3.14 billion	547.44

RYTHM’s competitors have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares RYTHM and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
RYTHM Competitors	-2,319.23%	-223.52%	-16.98%

Risk and Volatility

RYTHM has a beta of 9.44, meaning that its share price is 844% more volatile than the S&P 500. Comparatively, RYTHM’s competitors have a beta of -3.17, meaning that their average share price is 417% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for RYTHM and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1	0	0	0	1.00
RYTHM Competitors	7615	13666	25498	1003	2.42

As a group, “Pharmaceuticals” companies have a potential upside of 28.46%. Given RYTHM’s competitors stronger consensus rating and higher probable upside, analysts plainly believe RYTHM has less favorable growth aspects than its competitors.

Summary

RYTHM competitors beat RYTHM on 9 of the 13 factors compared.

About RYTHM

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.